Plain-English translation of NCT07407166 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial evaluates how effective is when used as the first treatment for metastatic melanoma (melanoma that has spread beyond the skin). You would receive standard and have regular imaging scans and blood tests to see how well the treatment is working. The study also collects samples to identify which patients respond best to this medication.
has become a standard first treatment for advanced melanoma, but it works much better for some patients than others. This trial aims to discover biological markers—visible clues in blood, stool, and body fluid samples—that can predict which patients will benefit most from the treatment and which patients might need different approaches.
You likely qualify if…
You likely don't qualify if…
You would receive your standard treatment while being monitored closely by the study team. You would have imaging scans (CT or PET scans) at the start, then at 4 weeks, 12 weeks, and 28 weeks to see how well the treatment is working. At these same time points, you would also donate small samples of blood and stool, and any fluid samples if they are collected for medical reasons. The study lasts approximately 7 months, with visits coordinated around your regular cancer care appointments.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Slovenia